Genmab Management

Management criteria checks 4/4

Genmab's CEO is Jan G.J. de Winkel, appointed in Jun 2010, has a tenure of 15.58 years. total yearly compensation is $7.61M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth $221.46M. The average tenure of the management team and the board of directors is 7 years and 7.8 years respectively.

Key information

Jan G.J. de Winkel

Chief executive officer

US$7.6m

Total compensation

CEO salary percentage	17.70%
CEO tenure	15.6yrs
CEO ownership	1.1%
Management average tenure	7yrs
Board average tenure	7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jan G.J. de Winkel's remuneration changed compared to Genmab's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2025	n/a	n/a	US$2b
Jun 30 2025	n/a	n/a	US$1b
Mar 31 2025	n/a	n/a	US$1b
Dec 31 2024	US$8m	US$1m	US$1b
Sep 30 2024	n/a	n/a	US$702m
Jun 30 2024	n/a	n/a	US$798m
Mar 31 2024	n/a	n/a	US$791m
Dec 31 2023	US$7m	US$1m	US$645m
Sep 30 2023	n/a	n/a	US$590m
Jun 30 2023	n/a	n/a	US$680m
Mar 31 2023	n/a	n/a	US$757m
Dec 31 2022	US$6m	US$1m	US$785m
Sep 30 2022	n/a	n/a	US$745m
Jun 30 2022	n/a	n/a	US$558m
Mar 31 2022	n/a	n/a	US$354m
Dec 31 2021	US$6m	US$1m	US$452m
Sep 30 2021	n/a	n/a	US$448m
Jun 30 2021	n/a	n/a	US$401m
Mar 31 2021	n/a	n/a	US$880m
Dec 31 2020	US$6m	US$1m	US$781m
Sep 30 2020	n/a	n/a	US$889m
Jun 30 2020	n/a	n/a	US$853m
Mar 31 2020	n/a	n/a	US$349m
Dec 31 2019	US$5m	US$1m	US$325m

Compensation vs Market: Jan G.J.'s total compensation ($USD7.61M) is below average for companies of similar size in the US market ($USD13.29M).

Compensation vs Earnings: Jan G.J.'s compensation has been consistent with company performance over the past year.

CEO

Jan G.J. de Winkel (64 yo)

15.6yrs

Tenure

US$7,611,989

Compensation

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jan G.J. de Winkel	Co-Founder	15.6yrs	US$7.61m	1.07% $ 221.5m
Anthony Pagano	Executive VP & CFO	5.8yrs	US$3.33m	0.011% $ 2.4m
Rayne Waller	Executive VP & Chief Technical Operations Officer	1.4yrs	US$816.76k	no data
Christopher Cozic	Executive VP & Chief People Officer	8.2yrs	US$2.31m	no data
Martine van Vugt	Executive VP & Chief Strategy Officer	12yrs	US$1.51m	no data
Martin Schultz	Senior Director	no data	US$194.47k	0.00065% $ 134.6k
Judith Klimovsky	Executive VP & Chief Development Officer	8.9yrs	US$3.88m	0.018% $ 3.6m
Tahamtan Ahmadi	Executive VP	4.8yrs	US$3.58m	0.0079% $ 1.6m
Mijke Zachariasse	VP, Head of Antibody Research Materials & Director	no data	US$222.25k	0.0011% $ 231.9k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	US$194.47k	0.00013% $ 26.9k
Brad Bailey	Executive VP & Chief Commercial Officer	1.4yrs	US$2.30m	no data
Andrew Carlsen	VP & Head of Investor Relations	no data	no data	no data

7.0yrs

Average Tenure

53yo

Average Age

Experienced Management: GNMS.F's management team is seasoned and experienced (7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Martin Schultz	Senior Director	4yrs	US$194.47k	0.00065% $ 134.6k
Mijke Zachariasse	VP, Head of Antibody Research Materials & Director	6.8yrs	US$222.25k	0.0011% $ 231.9k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	4yrs	US$194.47k	0.00013% $ 26.9k
Michael Kavanagh	Senior Director	1yr	no data	no data
Anders Pedersen	Non-Independent Director	22.2yrs	US$291.70k	0.013% $ 2.6m
Elizabeth O'Farrell	Independent Director	3.8yrs	US$361.15k	0.0031% $ 633.5k
Deirdre Connelly	Independent Chairman of the Board	8.8yrs	US$458.39k	0.011% $ 2.2m
Rolf Hoffmann	Independent Director	8.8yrs	US$277.81k	0.0061% $ 1.3m
Pernille Erenbjerg	Independent Deputy Chairman	11yrs	US$361.15k	0.0089% $ 1.8m
Paolo Paoletti	Independent Director	11yrs	US$263.92k	0.0041% $ 842.6k

7.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: GNMS.F's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/15 23:14
End of Day Share Price	2026/01/15 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genmab A/S is covered by 45 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Gordon	Barclays
Xue Chen	Barclays
Emily Field	Barclays

Genmab Management

Management criteria checks 4/4

Key information

Recent management updates

Genmab Announces Changes to Its Executive Committee

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Announces Executive Changes

Genmab A/S Announces Executive Changes

Genmab A/S, Annual General Meeting, Mar 13, 2024

Recent updates

Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S to Report First Half, 2026 Results on Aug 06, 2026

Genmab Provides Earnings Guidance for the Full Year 2025

Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Genmab Reportedly in Advanced Talks to Buy Merus

Genmab A/S Announces Updated Results from Phase 2 Epcore®? Nhl-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)

Genmab A/S Raises Earnings Guidance for the Year 2025

Genmab Announces Changes to Its Executive Committee

Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial

Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association (Eha) Congress

Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma

Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer

Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-S

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Provides Revenue Guidance for 2025

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces That Janssen Has Received European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-Chain (Al) Amyloidosis

CEO Compensation Analysis

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources